Cargando…

Private Payer Coverage Policies for ApoE-e4 Genetic Testing

PURPOSE: ApoE-e4 has a well-established connection to late-onset Alzheimer’s disease (AD) and is available clinically. Yet, there have been no analyses of payer coverage policies for ApoE. Our objective is to analyze private payer coverage policies for ApoE genetic testing, examine the rationales, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arias, Jalayne J., Tyler, Ana M., Douglas, Michael P., Phillips, Kathryn A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035237/ https://www.ncbi.nlm.nih.gov/pubmed/33420342 http://dx.doi.org/10.1038/s41436-020-01042-4

Ejemplares similares

Private Payer Coverage Policies for Whole Exome Sequencing (WES) in Pediatric Patients: Trends Over Time and Analysis of Evidence Cited
por: Douglas, Michael P., et al.
Publicado: (2018)

Variation in Private Payer Coverage of Rheumatoid Arthritis Drugs
por: Chambers, James D., et al.
Publicado: (2016)

A Private Payer Persective
por: Shurney, Dexter W.
Publicado: (2006)

Variability in Private Payer Medical Policies for Osteochondral Allograft Transplantation Demonstrates the Absence of Standardization in Medical Criteria Between Payers
por: Tabbaa, Suzanne M., et al.
Publicado: (2022)

US public and private payer coverage for tobacco cessation treatments and barriers to accessing treatments
por: Hussain, Radha, et al.
Publicado: (2022)

The growth and gaps of genetic data sharing policies in the United States
por: Arias, Jalayne J., et al.
Publicado: (2014)

Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies
por: Chambers, James D., et al.
Publicado: (2018)

Harnessing the paradoxical phenotypes of APOE ɛ2 and APOE ɛ4 to identify genetic modifiers in Alzheimer's disease
por: Kim, Young Won, et al.
Publicado: (2020)

Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice
por: Hu, Jin, et al.
Publicado: (2015)

How do Medicare Physician Fees Compare With Private Payers?
por: Miller, Mark E., et al.
Publicado: (1993)

Understanding the evolution of coverage policies for prophylaxis treatments of hemophilia A without inhibitors: a payer Delphi panel
por: Graf, Marlon, et al.
Publicado: (2021)

Actuarial Analysis of Private Payer Administrative Claims Data for Women With Endometriosis
por: Mirkin, David, et al.
Publicado: (2007)

Specialty Pharmacy Cost Management Strategies of Private Health Care Payers
por: Stern, Debbi, et al.
Publicado: (2006)

Commentary: Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk
por: Dzianok, Patrycja, et al.
Publicado: (2020)

Mercury Ion Binding to Apolipoprotein E Variants ApoE2, ApoE3, and ApoE4: Similar Binding Affinities but Different Structure Induction Effects
por: Berntsson, Elina, et al.
Publicado: (2022)

ApoE4 Induces Synaptic and ERG Impairments in the Retina of Young Targeted Replacement ApoE4 Mice
por: Antes, Ran, et al.
Publicado: (2013)

ApoE and apoE receptors in brain lipid metabolism and AD
por: Bu, Guojun
Publicado: (2012)

ApoE e4e4 Genotype and Mortality With COVID-19 in UK Biobank
por: Kuo, Chia-Ling, et al.
Publicado: (2020)

Sex Differences in Presynaptic Density and Neurogenesis in Middle-Aged ApoE4 and ApoE Knockout Mice
por: Rijpma, A., et al.
Publicado: (2013)

Opposing effects of apoE2 and apoE4 on microglial activation and lipid metabolism in response to demyelination
por: Wang, Na, et al.
Publicado: (2022)

Apolipoprotein E (ApoE) ε4 Genotype (ApoE rs429358—ApoE rs7412 Polymorphisms) Is Not Associated with Long COVID Symptoms in Previously Hospitalized COVID-19 Survivors
por: Fernández-de-las-Peñas, César, et al.
Publicado: (2023)

Association of opioid fills with centers for disease control and prevention opioid guidelines and payer coverage policies: physician, insurance and geographic factors
por: Togun, Adeniyi T., et al.
Publicado: (2021)

Vascular hypothesis of Alzheimer’s disease: role of apoE and apoE receptors
por: Bu, Guojun, et al.
Publicado: (2013)

Payer reimbursement practices and incentives for improving interpretation of germline genetic testing
por: Deverka, Patricia, et al.
Publicado: (2023)

Comment on: “Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective”
por: Liedgens, Hiltrud, et al.
Publicado: (2013)

Payer Policy Behavior Towards Opioid Pharmacotherapy Treatment in Ohio
por: Molfenter, Todd, et al.
Publicado: (2018)

The effect of ApoE e4 on blood pressure in patients with and without depression
por: Hestad, Knut A, et al.
Publicado: (2016)

Lipoprotein glomerulopathy induced by ApoE Kyoto mutation in ApoE-deficient mice
por: Wu, Hongyan, et al.
Publicado: (2021)

ApoE4 induces Aβ42, tau, and neuronal pathology in the hippocampus of young targeted replacement apoE4 mice
por: Liraz, Ori, et al.
Publicado: (2013)

ApoE4 Astrocytes Secrete Basement Membranes Rich in Fibronectin and Poor in Laminin Compared to ApoE3 Astrocytes
por: Keable, Abby, et al.
Publicado: (2020)

ApoE polymorphisms in narcolepsy
por: Gencik, Martin, et al.
Publicado: (2001)

On the determinants and the role of the payers in the uptake of genetic testing and data sharing in personalized health
por: Kalouguina, Veronika, et al.
Publicado: (2023)

Plasma Apolipoprotein E3 and Glucose Levels Are Associated in APOE ɛ3/ɛ4 Carriers
por: Edlund, Anna K., et al.
Publicado: (2021)

Disparity in clinical outcomes after cardiac surgery between private and public (NHS) payers in England
por: Benedetto, Umberto, et al.
Publicado: (2020)

Financial Burden of Discarded Weight-based Antineoplastic Drugs to Payers and Patients in the Private Insurance Market
por: Shih, Ya-Chen Tina, et al.
Publicado: (2021)

Application of Economic Analyses in U.S. Managed Care Formulary Decisions: A Private Payer's Experience
por: Watkins, John B., et al.
Publicado: (2006)

Possible relationship of the apolipoprotein E (ApoE) epsilon4 allele to prostate cancer.
por: Lehrer, S.
Publicado: (1998)

ApoE3 vs. ApoE4 Astrocytes: A Detailed Analysis Provides New Insights into Differences in Cholesterol Homeostasis
por: Staurenghi, Erica, et al.
Publicado: (2022)

Potential role of ATM in hepatocyte endocytosis of ApoE-deficient, ApoB48-containing lipoprotein in ApoE-deficient mice
por: WU, JIANHUA, et al.
Publicado: (2014)

ApoE4: an emerging therapeutic target for Alzheimer’s disease
por: Safieh, Mirna, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ks56pis918t8ifgveq6n56ln73